Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance   Basel, Switzerland, 29 June 2021 - Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza today is providing restated financials to reflect: [ … ]

A new drug substance production line at Lonza's site in Geleen, Netherlands will complement the existing production network and support the manufacture of up to an additional 300 million doses per year  Operations are expected to begin by the end of 2021 Quote from Jean-Christophe Hyvert, President, Biologics and Cell & Gene, Lonza: 'Once mor [ … ]

Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market A new large-scale facility with the latest manufacturing technology in Visp (CH), will expand capacity by six 20,000L bioreactors to meet increasing mark [ … ]